Cipher Pharmaceuticals Inc. (TSE:CPH - Free Report) NASDAQ: CPHR - Equities researchers at Leede Financial issued their FY2027 earnings per share (EPS) estimates for shares of Cipher Pharmaceuticals in a report issued on Wednesday, March 19th. Leede Financial analyst D. Loe expects that the company will post earnings per share of $1.10 for the year. The consensus estimate for Cipher Pharmaceuticals' current full-year earnings is $1.29 per share.
Shares of Cipher Pharmaceuticals stock opened at C$13.14 on Monday. The business has a fifty day simple moving average of C$12.91 and a two-hundred day simple moving average of C$14.46. Cipher Pharmaceuticals has a 1 year low of C$7.90 and a 1 year high of C$19.69. The company has a market capitalization of C$235.91 million, a price-to-earnings ratio of 14.51 and a beta of 1.20. The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67.
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.